While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, 21 May 2024
New York-based biotech Regeneron Pharmaceuticals has announced highly encouraging results from a trial of its investigational gene therapy DB-OTO. 9 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.